Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide plus ADT versus placebo plus ADT in metastatic hormone-sensitive prostate cancer
2020-003093-48Phase 3Active
- Sponsor
- Bayer Consumer Health
- Start
- Nov 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Darolutamide plus ADT with Placebo plus ADT (2 arms). Primary endpoint: Radiological progression-free survival. Started Nov 2020; status: active.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2020-003093-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003093-48.